Bill
Bill > HB1384
summary
Introduced
02/13/2026
02/13/2026
In Committee
02/13/2026
02/13/2026
Crossed Over
Passed
Dead
04/13/2026
04/13/2026
Introduced Session
2026 Regular Session
Bill Summary
Requiring, on or before July 1, 2028, the Maryland Department of Health to select and contract with a State pharmacy benefits manager; requiring that each managed care contract entered into or renewed after July 1, 2028, require the managed care organization to contract with and use the State pharmacy benefits manager; and requiring the Department to engage an independent consultant to advise it in selecting and contracting with the State pharmacy benefits manager.
AI Summary
This bill mandates that by July 1, 2028, the Maryland Department of Health must select and contract with a single entity to act as the State Pharmacy Benefits Manager (SPBM). A Pharmacy Benefits Manager (PBM) is defined as a person or company that manages prescription drug benefits, including negotiating drug prices, processing claims, and managing formularies. The SPBM will be responsible for administering pharmacy benefits for all recipients of the Maryland Medical Assistance Program, including those enrolled in managed care organizations (MCOs), which are private companies contracted by the state to provide healthcare services to program recipients. Consequently, any new or renewed managed care contracts after July 1, 2028, will require MCOs to use the SPBM for their pharmacy benefits. To assist in selecting and contracting with the SPBM, the Department of Health will hire an independent consultant with specific experience in advising Medicaid fraud control units and working with states that have already established a single PBM for their Medicaid programs, ensuring this consultant has no conflicts of interest with MCOs or PBMs. The bill also outlines specific requirements for the SPBM contract, including establishing a fiduciary duty to the Department, mandating "pass-through pricing" (where the price charged to the program is the same as the price paid to the pharmacy), requiring the use of state-negotiated formularies and dispensing fees, demanding transparency in all drug-related costs and fees, and explicitly prohibiting "spread pricing," a practice where a PBM charges more than it pays for a drug.
Committee Categories
Health and Social Services
Sponsors (1)
Last Action
Withdrawn by Sponsor (on 03/20/2026)
Bill Topics
Health
- ‐ Health Insurance Reform
- ‐ Regulation of Drug Industry and Pharmacies
bill text
bill summary
Loading...
bill summary
Loading...
bill summary
| Document Type | Source Location | Created |
|---|---|---|
| State Bill Page | https://mgaleg.maryland.gov/mgawebsite/Legislation/Details/HB1384?ys=2026RS | 02/13/2026 |
| Vote Image | https://mgaleg.maryland.gov/2026RS/votes_comm/hb1384_hlt.pdf | 03/20/2026 |
| BillText | https://mgaleg.maryland.gov/2026RS/bills/hb/hb1384f.pdf | 02/13/2026 |
Loading...